CN108567792A - 一种治疗阿尔茨海默病的复合维生素组合物 - Google Patents

一种治疗阿尔茨海默病的复合维生素组合物 Download PDF

Info

Publication number
CN108567792A
CN108567792A CN201710131111.XA CN201710131111A CN108567792A CN 108567792 A CN108567792 A CN 108567792A CN 201710131111 A CN201710131111 A CN 201710131111A CN 108567792 A CN108567792 A CN 108567792A
Authority
CN
China
Prior art keywords
vitamin
parts
composition
use according
vitamins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710131111.XA
Other languages
English (en)
Chinese (zh)
Inventor
周明东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Priority to CN201710131111.XA priority Critical patent/CN108567792A/zh
Priority to CN201880015481.XA priority patent/CN110520135A/zh
Priority to EP24189913.7A priority patent/EP4461361A3/en
Priority to BR112019018652A priority patent/BR112019018652A2/pt
Priority to CA3054972A priority patent/CA3054972A1/en
Priority to JP2019548652A priority patent/JP7169285B2/ja
Priority to ES18763903T priority patent/ES2989651T3/es
Priority to EP18763903.4A priority patent/EP3593805B1/en
Priority to PCT/CN2018/077107 priority patent/WO2018161808A1/zh
Priority to AU2018229920A priority patent/AU2018229920B2/en
Priority to US16/491,560 priority patent/US11464797B2/en
Publication of CN108567792A publication Critical patent/CN108567792A/zh
Priority to US17/945,684 priority patent/US20230248756A1/en
Priority to JP2022172956A priority patent/JP2023011769A/ja
Priority to AU2024202678A priority patent/AU2024202678A1/en
Priority to JP2024198677A priority patent/JP2025024089A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201710131111.XA 2017-03-07 2017-03-07 一种治疗阿尔茨海默病的复合维生素组合物 Pending CN108567792A (zh)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CN201710131111.XA CN108567792A (zh) 2017-03-07 2017-03-07 一种治疗阿尔茨海默病的复合维生素组合物
EP18763903.4A EP3593805B1 (en) 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
PCT/CN2018/077107 WO2018161808A1 (zh) 2017-03-07 2018-02-24 维生素组合物在制备用于预防、治疗或延迟阿尔茨海默病的药物中的用途
BR112019018652A BR112019018652A2 (pt) 2017-03-07 2018-02-24 uso de composição de vitaminas
CA3054972A CA3054972A1 (en) 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
JP2019548652A JP7169285B2 (ja) 2017-03-07 2018-02-24 アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用
ES18763903T ES2989651T3 (es) 2017-03-07 2018-02-24 Uso de una composición vitamínica para preparar un fármaco para prevenir, tratar o retrasar la enfermedad de Alzheimer
CN201880015481.XA CN110520135A (zh) 2017-03-07 2018-02-24 维生素组合物在制备用于预防、治疗或延迟阿尔茨海默病的药物中的用途
EP24189913.7A EP4461361A3 (en) 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
AU2018229920A AU2018229920B2 (en) 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying Alzheimer's disease
US16/491,560 US11464797B2 (en) 2017-03-07 2018-02-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying Alzheimer's disease
US17/945,684 US20230248756A1 (en) 2017-03-07 2022-09-15 Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
JP2022172956A JP2023011769A (ja) 2017-03-07 2022-10-28 アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用
AU2024202678A AU2024202678A1 (en) 2017-03-07 2024-04-24 Use of vitamin composition in preparing drug for preventing, treating, or delaying Alzheimer's disease
JP2024198677A JP2025024089A (ja) 2017-03-07 2024-11-14 アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710131111.XA CN108567792A (zh) 2017-03-07 2017-03-07 一种治疗阿尔茨海默病的复合维生素组合物

Publications (1)

Publication Number Publication Date
CN108567792A true CN108567792A (zh) 2018-09-25

Family

ID=63448062

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710131111.XA Pending CN108567792A (zh) 2017-03-07 2017-03-07 一种治疗阿尔茨海默病的复合维生素组合物
CN201880015481.XA Pending CN110520135A (zh) 2017-03-07 2018-02-24 维生素组合物在制备用于预防、治疗或延迟阿尔茨海默病的药物中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880015481.XA Pending CN110520135A (zh) 2017-03-07 2018-02-24 维生素组合物在制备用于预防、治疗或延迟阿尔茨海默病的药物中的用途

Country Status (9)

Country Link
US (2) US11464797B2 (enExample)
EP (2) EP4461361A3 (enExample)
JP (3) JP7169285B2 (enExample)
CN (2) CN108567792A (enExample)
AU (2) AU2018229920B2 (enExample)
BR (1) BR112019018652A2 (enExample)
CA (1) CA3054972A1 (enExample)
ES (1) ES2989651T3 (enExample)
WO (1) WO2018161808A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021023069A1 (zh) * 2019-08-02 2021-02-11 上海日馨生物科技有限公司 Tpk作为靶点在阿尔茨海默病的应用
CN119055674A (zh) * 2024-11-06 2024-12-03 中国医学科学院北京协和医院 一种可改善认知的组合物及其在阿尔茨海默病防治中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102275981B1 (ko) * 2020-03-31 2021-07-13 고려은단주식회사 섬쑥부쟁이 추출물과 비타민 b 복합체의 혼합물을 포함하는 인지기능 개선용 조성물
AU2022464309A1 (en) * 2022-06-22 2025-01-23 Biomedical Research Group Inc. Prophylactic drug and therapeutic drug for diabetes-associated dementia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275591A1 (en) * 2004-12-01 2011-11-10 Concourse Health Sciences Llc Cocktail for modulation of alzheimer's disease
CN102843922A (zh) * 2010-05-13 2012-12-26 尼特罗米加公司 硝基脂肪酸–认知减退的神经保护和/或抑制
US20150238527A1 (en) * 2012-08-10 2015-08-27 Aquavit Pharmaceuticals, Inc. Vitamin supplement compositions for injection
CN106265696A (zh) * 2015-06-12 2017-01-04 上海泽生科技开发有限公司 使用复合维生素b、c组合物促进胃肠系统动力的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626884A (en) 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
DE69930746T2 (de) 1998-06-10 2007-03-15 Crum, Albert B. Vorbeugender und therapeutischer nahrungsmittelzusatz zur schaffung/erhaltung einer die gesundheit schützenden darmmikroflora und zur stärkung des immunsystems
WO2003082339A1 (en) 2002-03-22 2003-10-09 Doc's Guide, Inc. Multivitamin and mineral nutritional supplement
CA2583972A1 (en) 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
US20060148727A1 (en) * 2004-12-01 2006-07-06 Curt Hendrix Folate based composition for neurological and cognitive applications
NZ582329A (en) * 2007-06-26 2012-09-28 Nutricia Nv Improving memory in subjects with mini-mental state examination of 24-26
US9763989B2 (en) * 2007-08-03 2017-09-19 Shaklee Corporation Nutritional supplement system
JP4206428B1 (ja) * 2008-06-09 2009-01-14 正樹 今川 認知症を処置するための組成物及びその利用
KR20110004691A (ko) * 2009-07-08 2011-01-14 대한민국(농촌진흥청장) 뇌기능 개선효과를 가지는 붉나무 추출물을 포함하는 약학조성물 및 건강식품조성물
EP2554057A4 (en) * 2010-03-31 2013-12-18 Vegenat S A ENERAL OR ORAL FOOD PRODUCT SPECIALLY FOR NUTRITION, PREVENTION AND MITIGATION OF NEUROLOGICAL OR NEURODEGENERATIVE ALTERATIONS OR COGNITIVE DISORDERS
WO2012012682A2 (en) 2010-07-22 2012-01-26 Zishan Haroon Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
KR20130015932A (ko) * 2011-08-05 2013-02-14 연세대학교 산학협력단 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물
WO2013066151A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
BR112014020177A8 (pt) * 2012-03-02 2021-10-19 Nutricia Nv Uso de uma composição para a fabricação de um produto para diminuir, prevenir ou reverter a conectividade cerebral funcional prejudicada e/ou organização da rede cerebral prejudicada
EP2882304A1 (en) * 2012-08-07 2015-06-17 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
CN104337813A (zh) 2013-07-23 2015-02-11 上海泽生科技开发有限公司 使用维生素b组合物促进胃肠系统动力的方法
CN104256652A (zh) 2014-10-08 2015-01-07 李明刚 一种口服复合维生素纳米脂质体
CN104922164B (zh) * 2014-12-12 2020-06-02 中国医科大学 一种治疗阿尔茨海默病的药物复合制剂
CN104856048A (zh) 2015-06-18 2015-08-26 安徽医联大成医药科技有限公司 一种促进肠胃蠕动的食品配方及其制备方法
CN108079008A (zh) * 2016-11-23 2018-05-29 上海泽生科技开发股份有限公司 促进胃肠系统动力的复合维生素组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275591A1 (en) * 2004-12-01 2011-11-10 Concourse Health Sciences Llc Cocktail for modulation of alzheimer's disease
CN102843922A (zh) * 2010-05-13 2012-12-26 尼特罗米加公司 硝基脂肪酸–认知减退的神经保护和/或抑制
US20150238527A1 (en) * 2012-08-10 2015-08-27 Aquavit Pharmaceuticals, Inc. Vitamin supplement compositions for injection
CN106265696A (zh) * 2015-06-12 2017-01-04 上海泽生科技开发有限公司 使用复合维生素b、c组合物促进胃肠系统动力的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
岳志霞等: "脑室内注射链脲佐菌素大鼠海马神经元和突触的超微结构异常", 《电子显微学报》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021023069A1 (zh) * 2019-08-02 2021-02-11 上海日馨生物科技有限公司 Tpk作为靶点在阿尔茨海默病的应用
CN114710952A (zh) * 2019-08-02 2022-07-05 上海日馨医药科技股份有限公司 Tpk作为靶点在阿尔茨海默病的应用
CN119055674A (zh) * 2024-11-06 2024-12-03 中国医学科学院北京协和医院 一种可改善认知的组合物及其在阿尔茨海默病防治中的应用

Also Published As

Publication number Publication date
JP2020509072A (ja) 2020-03-26
US20200030358A1 (en) 2020-01-30
US20230248756A1 (en) 2023-08-10
JP2023011769A (ja) 2023-01-24
CA3054972A1 (en) 2018-09-13
AU2024202678A1 (en) 2024-05-16
JP2025024089A (ja) 2025-02-19
JP7169285B2 (ja) 2022-11-10
EP3593805A1 (en) 2020-01-15
US11464797B2 (en) 2022-10-11
BR112019018652A2 (pt) 2020-04-07
CN110520135A (zh) 2019-11-29
ES2989651T3 (es) 2024-11-27
EP4461361A3 (en) 2025-01-01
EP4461361A2 (en) 2024-11-13
EP3593805A4 (en) 2020-10-07
WO2018161808A1 (zh) 2018-09-13
AU2018229920A1 (en) 2019-10-03
AU2018229920B2 (en) 2024-02-08
EP3593805B1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
Geisler et al. DNP, mitochondrial uncoupling, and neuroprotection: A little dab'll do ya
JP6676062B2 (ja) 認知低下を処置するための方法
Stephen et al. Integrating pharmacological and psychosocial treatments for schizophrenia
US20230248756A1 (en) Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
Miao et al. Tetrahydroxy stilbene glucoside alters neurogenesis and neuroinflammation to ameliorate radiation-associated cognitive disability via AMPK/Tet2
US20090286750A1 (en) Use of ribose in lessening the clinical symptoms of aberrant firing of neurons
CN106389740A (zh) 一种预防和/或延缓老年轻度认知障碍的组合物及其使用方法
JP5856725B2 (ja) うつ病治療用または予防用医薬組成物
WO2011041920A2 (es) Composición nutracéutica que comprende extracto de shilajit, ácido fólico, vitamina b12 y vitamina b6 y su uso para prevenir y/o tratar enfermedades neurodegenerativas y/o el deterioro cognitivo asociado al envejecimiento cerebral
WO2022007982A2 (zh) 一种药物组合物及其应用
CN112569237A (zh) 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用
CN104906501A (zh) 治疗银屑病的中药组分组合物
CN114072154A (zh) 用于治疗精神障碍的加波沙朵和锂的组合物
Cao et al. The potential role and mechanism of Rhizoma Coptidis in prevention of diabetic encephalopathy: targeting sodium ion and channels
WO2023273626A1 (zh) 一种治疗老年性痴呆的组合物及其制备方法
Hoffer Negative and positive side effects of vitamin B3
Miculas et al. Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions. Cells 2023, 12, 131
CA2735949C (en) Use of ribose in lessening the clinical symptoms of aberrant firing of neurons
CN120939027A (zh) 药物组合物的用途
CN116832022A (zh) 用于预防和治疗老年性痴呆的药物组合物
CN117957003A (zh) 治疗神经退行性疾病的方法
HK40065529A (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
Story et al. What the Evidence Tells Us About Brain Health Supplements for Alzheimer’s Disease
Chua Randomized controlled clinical trials for the evaluation of efficacy and safety of Chinese medicine in treatment of neurodegenerative diseases
Wollen Alzheimer's Disease Therapies That Have Shown Some Promise But Have Insufficient Supporting Evidence

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180925